Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 92 clinical trials
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

This is a Phase 1b, multicenter, open-label, PK, and safety study of multiple oral doses of oral decitabine and cedazuridine (formerly known as ASTX727) as a fixed-dose combination of decitabine

lymphoma
decitabine
acute promyelocytic leukemia
hematologic malignancy
aml/mds
  • 0 views
  • 25 Mar, 2022
  • 1 location
A Study of CFI-400945 With or Without Azacitidine or Decitabine in Patients With AML MDS or CMML

The purpose of this study is to test the safety of an investigational drug called CFI-400945 alone and in combination with azacitidine or decitabine

refractory acute myeloid leukemia (aml)
decitabine
azacitidine
  • 0 views
  • 25 Jun, 2021
  • 2 locations
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

This phase II trial studies how well venetoclax and decitabine work in treating participants with acute myeloid leukemia that has come back or does not respond to treatment, or with high-risk

gilbert's syndrome
hydroxyurea
acute leukemia
TP53
complex karyotype
  • 54 views
  • 02 May, 2022
  • 1 location
Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

This phase II trial studies the effects of venetoxlax in combination with decitabine and cedazuridine in treating patients with acute myeloid leukemia that has come back (relapsed) or does not

  • 0 views
  • 16 May, 2022
  • 1 location
Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia

. ASTX727 is the combination of a fixed dose of 2 drugs, cedazuridine and decitabine. Cedazuridine may slow down how fast decitabine is broken down by the body, and decitabine may block abnormal cells or

  • 0 views
  • 26 Apr, 2022
  • 1 location
Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

This phase I/II trial studies the side effects and best dose of venetoclax in combination with cedazuridine and decitabine (ASTX727) in treating patients with high risk myelodysplastic syndrome

decitabine
hydroxyurea
myelomonocytic leukemia
chronic myelomonocytic leukemia
cancer
  • 0 views
  • 05 Nov, 2021
  • 1 location
Decitabine Venetoclax and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

This phase II trial studies how well the combination of decitabine, venetoclax, and ponatinib work for the treatment of Philadelphia chromosome-positive acute myeloid leukemia or myeloid blast

amylase
gilbert's syndrome
remission
serum bilirubin level
venetoclax
  • 0 views
  • 06 Nov, 2021
  • 1 location
Decitabine Alone or in Combination With Venetoclax Gilteritinib Enasidenib or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

This phase Ib trial is to find out the side effects and possible benefits of decitabine alone or given together with venetoclax, gilteritinib, enasidenib, or ivosidenib in treating patients with

enasidenib
residual tumor
consolidation therapy
decitabine
remission
  • 0 views
  • 01 Dec, 2021
  • 1 location
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

The goal of this clinical research study is to learn if cladribine given in combination with low-dose cytarabine (LDAC) and decitabine can help control the disease in patients with AML or MDS

blast cells
decitabine
hydroxyurea
myeloid leukemia
cytarabine
  • 12 views
  • 21 Nov, 2021
  • 1 location
Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients

The purpose of this study is to evaluate the efficacy and safety of decitabine combined with HAAG regimen in the treatment of newly diagnosed patients with ETP-ALL/LBL, T/M-MPAL and ALL/LBL with

treatment regimen
chemotherapy regimen
  • 0 views
  • 24 Jan, 2021
  • 1 location